Categories Earnings, Technology

Jabil tops Q2 earnings, meets revenue estimates

Jabil Inc (JBL) surpassed earnings estimates, while meeting revenue targets for Q2 2019. The company posted earnings of $0.64 per share on revenue of $6.1 billion. Analysts had predicted Jabil to report earnings of $0.61 per share on revenue of $6.1 billion for the second quarter. Shares of Jabil are up about 2% during the extended trading hours.

On a GAAP basis, earnings stood at 43 cents per share. Diversified Manufacturing Services (DMS) revenue decreased 7% compared to the prior year quarter, while Electronics Manufacturing Services (EMS) revenue grew 33% in the recently ended quarter.

For the second quarter, the company had expected net revenue in the range of $5.8 billion to $6.4 billion and earnings in the range of $0.20 to $0.48 per share. Core (non-GAAP) earnings were anticipated to be in the range of $0.51 to $0.71 per share. DMS revenue was predicted to rise 6% and EMS revenue was expected to grow by 23% from the previous year.

Check out the earnings call audios of Jabil here

“As we move into the back half of our fiscal year, our outlook for revenue and core EPS remain strong, supported by strength in our healthcare, retail, cloud and industrial businesses,” said CEO Mark Mondello.

For Q3 2019, Jabil expects revenue to be in the range of $5.7 billion to $6.3 billion. DMS revenue is expeced to decrease 12% year-over-year, while EMS revenue is targeted to increase 27%. GAAP EPS is estimated to be $0.19 to $0.46 and core (non-GAAP) EPS is expected to be in the range of $0.47 to $0.67.

Jabil’s stock value has appreciated 10% so far in this year and depreciated 3% in the past 52 weeks period.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top